Lee's Pharm (00950) has announced that its wholly-owned subsidiary, Lee's Pharm (Hong Kong) Limited, has entered into an exclusive licensing agreement with US-based biotechnology firm 1cBio, Inc. to develop, manufacture, and commercialize OC-3 across mainland China, Hong Kong, Macau, Taiwan, and select Southeast Asian countries.

OC-3 is a PARP1 inhibitor designed to target cancers with DNA homologous recombination repair deficiencies, including prostate, ovarian, breast, and pancreatic cancers characterized by mutations in known DNA repair genes such as BRCA1, BRCA2, or PALB2.

Under the terms of the agreement, Lee's Pharm (Hong Kong) will be responsible for conducting GLP safety studies and manufacturing activities necessary to secure regulatory approvals for OC-3 within the licensed territories. The deal also encompasses drug supply and production arrangements between the two parties.

1cBio retains the right to access and utilize data generated under the agreement to support its planned investigational new drug application submission to the US Food and Drug Administration.

The company believes this agreement will expand and diversify its oncology pipeline in the region by introducing a unique, potentially best-in-class PARP1 inhibitor, while complementing its existing infrastructure in drug development, clinical research, regulatory affairs, manufacturing, sales, and marketing across mainland China and the broader region.